News

Data show 37.5% of patients in study were found to have moderate to severe DD, with an average score of ≥2.

eGFR improved by 10.8% and creatinine decreased by 6.8% in patients who received PIT procedures.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

The COVID-19 pandemic has increased the usage of telemedicine tools in all medical fields.

Children treated with SSRIs and SGAs concurrently demonstrate higher waist circumference, BMI, and plasma total cholesterol compared to those on monotherapy.

Over half of patients attained target A1C <7%. while a third of patients attained target A1C of <8%.

Overweight/obese patients with elevated fasting blood glucose generally present with higher degrees of insulin resistance, inflammation, adverse cardiovascular disease risk profile.

New findings show patients were able to more than halve type 2 diabetes medication while improving diabetic and cardiovascular parameters in 8 weeks.

New SUPRASS-2 findings show the dual GIP/GLP-1 agonist provided superior type 2 diabetes management outcomes at 3 different doses.

Data show no evidence of increased risk of adverse events in patients aged ≥80 years, compared to patients aged 70 - 79 years.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The study author joins to highlight new ADA 2021 findings showing rivaroxaban's benefit for a subpopulation of diabetic patients.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

New data presented at ADA 2021 show GLP-1RA treatment is budget neutral in comparison to SoC, citing lower inpatient and outpatient cost.

New data show liraglutide reduced visceral, ectopic fat, with greater effects seen compared to weight loss.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Researchers found that different pets elicit different allergy responses in child participants.

Data presented at ADA 2021 supports the noninferiority of faricimab to aflibercept.

Nearly half of all never C difficile cases are found in nursing home communities.

Patients on placebo with a history of systemic non-steroidal immunosuppressants generally fared worse than their treatment-naïve counterparts.

Researchers cite a lack of knowledge on the disease and treatments, which they believe affect the quality of life of patients.

The approval was supported by 2 trials demonstrating treatment efficacy in reducing ocular itching and inflammation in the cornea.

The overall 90-day cumulative incidences of a first CDI episode was 1.9%.

Stephen Russell, MD, talks about promising new data that has the potential to provide a breakthrough for treating the most common mutation of the rare genetic eye disease.

Among 49,197 vaccinated employees at Mass General Brigham, 776 self-reported cutaneous reactions following the first dose.

Data show pain scores were significantly lower in ibuprofen treatment group compared to acetaminophen.

Investigators report on the implications of ethnicity and rheumatic diseases on South Korean patients with COVID-19.

An investigative team is skeptical on the involvement if autonomic nervous function in cases of idiopathic pulmonary fibrosis.